Skip to Main Content

Advertisement

Skip Nav Destination

Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 study

Blood (2017) 130 (20): 2186–2195.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement